Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment.
Adenosine Monophosphate
/ analogs & derivatives
Aged
Alanine
/ analogs & derivatives
Anti-Bacterial Agents
/ therapeutic use
C-Reactive Protein
/ metabolism
Dexamethasone
/ therapeutic use
Dyspnea
Humans
Lactate Dehydrogenases
Pneumonia
Prognosis
Retrospective Studies
SARS-CoV-2
COVID-19 Drug Treatment
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
23 Sep 2022
23 Sep 2022
Historique:
entrez:
5
10
2022
pubmed:
6
10
2022
medline:
12
10
2022
Statut:
ppublish
Résumé
Although some studies have reported prognostic factors for coronavirus disease 2019 (COVID-19), they were conducted before standard treatment with remdesivir and dexamethasone was implemented. This retrospective, observational study was conducted to evaluate various prognostic factors in patients with COVID-19 pneumonia receiving standard treatment with remdesivir and dexamethasone. Of 99 patients with COVID-19 pneumonia, 68 (68.7%) died within 30 days of hospitalization. The mean age was 71.3 years. Remdesivir and dexamethasone were administered to 80 (80.8%) and 84 (84.8%) patients, respectively. Early antibiotic treatment was administered to 70 patients (70.7%) within 5 days of hospitalization. Dexamethasone (79.4% vs 96.8%, P = .033) was more frequently administered in the survived group, whereas early antibiotics (60.3% vs 93.5%, P = .001) were less frequently administered. In the multivariate analysis, a high National Early Warning Score (NEWS; odds ratio [OR] 1.272), high Charlson Comorbidity Index (CCI; OR 1.441), and dyspnea (OR 4.033) were independent risk factors for 30-day mortality. There was no significant difference in age, sex, and vaccination doses between the survived and fatal groups. Lymphopenia, monocytopenia and high levels of C-reactive protein (CRP)/lactate dehydrogenase (LDH) reflected poor prognosis. NEWS, CCI, and dyspnea were predictors of 30-day mortality in patients with COVID-19 pneumonia. Early antibiotic use did not lower the 30-day mortality risk.
Identifiants
pubmed: 36197235
doi: 10.1097/MD.0000000000030474
pii: 00005792-202209230-00081
pmc: PMC9508954
doi:
Substances chimiques
Anti-Bacterial Agents
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Dexamethasone
7S5I7G3JQL
C-Reactive Protein
9007-41-4
Lactate Dehydrogenases
EC 1.1.-
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30474Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Eur J Epidemiol. 2020 Aug;35(8):763-773
pubmed: 32816244
Arch Intern Med. 2009 Mar 23;169(6):588-94
pubmed: 19307522
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Chim Acta. 2020 Oct;509:135-138
pubmed: 32531257
J Nutr Health Aging. 2021;25(10):1140-1144
pubmed: 34866140
J Infect Public Health. 2022 Jan;15(1):13-20
pubmed: 34861603
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Clin Res Cardiol. 2020 Dec;109(12):1491-1499
pubmed: 32537662
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2103-2109
pubmed: 33161221
Clin Nutr ESPEN. 2020 Dec;40:214-219
pubmed: 33183539
Cancers (Basel). 2021 Jan 26;13(3):
pubmed: 33530509
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
JAMA. 2021 Nov 23;326(20):2043-2054
pubmed: 34734975
Resuscitation. 2010 Aug;81(8):932-7
pubmed: 20637974
J Med Virol. 2020 Nov;92(11):2573-2581
pubmed: 32458459
PLoS One. 2021 Aug 26;16(8):e0256744
pubmed: 34437642
Int J Epidemiol. 2021 May 17;50(2):420-429
pubmed: 33683344
Crit Care Med. 2011 Aug;39(8):1913-21
pubmed: 21532476
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Clin Microbiol Infect. 2021 Jan;27(1):61-66
pubmed: 33010444
Am J Emerg Med. 2013 Mar;31(3):545-8
pubmed: 23380094
Clin Infect Dis. 2021 Dec 6;73(11):e4039-e4046
pubmed: 32852539
Infect Dis Rep. 2021 Oct 31;13(4):930-937
pubmed: 34842707
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143